All In Biotech

Drug Trial Radar · NCT04908189

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 729 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

729

Actual

Start

Jul 15, 2021

Primary completion

Nov 7, 2024

Study completion Nov 12, 2026

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jun 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will provide additional long-term safety and efficacy information.

Conditions

  • Psoriatic Arthritis

Interventions

  • DeucravacitinibDrug

    Specified dose on specified days

  • PlaceboOther

    Specified dose on specified days

  • ApremilastDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16Time frame: Week 16

Locations

138 sites in 18 countries. Site status is shown where the registry gives one.

  • Local Institution - 0149

    Mountain Brook, Alabama

  • Local Institution - 0212

    Sacramento, California

  • Local Institution - 0188

    Whittier, California

  • Local Institution - 0192

    Skokie, Illinois

  • Local Institution - 0203

    Hopkinsville, Kentucky

  • Local Institution - 0195

    Baton Rouge, Louisiana

  • Local Institution - 0169

    Cumberland, Maryland

  • Local Institution - 0034

    Okemos, Michigan

  • Local Institution - 0133

    Eagan, Minnesota

  • Local Institution - 0109

    Hattiesburg, Mississippi

  • Local Institution - 0108

    New York, New York

  • Local Institution - 0186

    Rochester, New York

  • Local Institution - 0196

    Charlotte, North Carolina

  • Local Institution - 0180

    Cleveland, Ohio

  • Local Institution - 0189

    Oklahoma City, Oklahoma

  • Local Institution - 0147

    Portland, Oregon

  • Local Institution - 0016

    Duncansville, Pennsylvania

  • Local Institution - 0182

    Summerville, South Carolina

  • Local Institution - 0167

    Lubbock, Texas

  • Local Institution - 0070

    Mesquite, Texas

  • Local Institution - 0184

    Plano, Texas

  • Local Institution - 0187

    Seattle, Washington

  • Local Institution - 0190

    Franklin, Wisconsin

  • Local Institution - 0175

    Milwaukee, Wisconsin

  • Local Institution - 0200

    Buenos Aires, Argentina

  • Local Institution - 0048

    La Plata, Buenos Aires, Argentina

  • Local Institution - 0038

    San Isidro, Buenos Aires, Argentina

  • Local Institution - 0039

    CABA, Distrito Federal, Argentina

  • Local Institution - 0171

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Local Institution - 0003

    Botany, New South Wales, Australia

  • Local Institution - 0018

    Parramatta, New South Wales, Australia

  • Local Institution - 0004

    Maroochydore, Queensland, Australia

  • Local Institution - 0099

    Woodville, South Australia, Australia

  • Local Institution - 0002

    Camberwell, Victoria, Australia

  • Local Institution - 0017

    Geelong, Victoria, Australia

  • Local Institution - 0078

    Brussels, Belgium

  • Local Institution - 0058

    Ghent, Belgium

  • Local Institution - 0061

    Liège, Belgium

  • Local Institution - 0001

    Québec, Canada

  • Local Institution - 0111

    Vancouver, British Columbia, Canada

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.